key: cord-0972594-kafi9o1y
authors: Annie, Frank H.; Sirbu, Cristian; Frazier, Keely R.; Broce, Mike; Lucas, B. Daniel
title: Hydroxychloroquine in hospitalized COVID‐19 patients: Real world experience assessing mortality
date: 2020-10-12
journal: Pharmacotherapy
DOI: 10.1002/phar.2467
sha: 2975b12dfb747b0aca7d31c41087f14dd060a38d
doc_id: 972594
cord_uid: kafi9o1y

INTRODUCTION: Hydroxychloroquine (HCQ) for COVID‐19 is presently being used off‐label or within a clinical trial. OBJECTIVES: We investigated a multinational COVID‐19 patient database of real world data containing outcomes and their relationship to HCQ use. The primary outcome was all‐cause mortality within 30 days follow‐up. METHODS: Retrospective cohort study of patients receiving HCQ within 48 hours of hospital admission. Medications, preexisting conditions, clinical measures on admission, and outcomes were recorded. RESULTS: Among patients with a diagnosis of COVID‐19 in our propensity matched cohort, the mean ages±SD were 62.3±15.9 years (53.7% male) and 61.9±16.0 years (53.0% male) in the HCQ and no‐HCQ groups, respectively. There was no difference in overall 30‐day mortality between the HCQ and no‐HCQ groups (HCQ 13.1%, n=367; No‐HCQ 13.6%, n=367; OR 0.95; 95% CI 0.62‐1.46) after propensity‐matching. Although statistically insignificant, the HCQ/azithromycin (AZ) group had an overall mortality rate of 14.6% (n=199) compared with propensity matched no HCQ/+AZ cohort’s rate of 12.1% (n=199) (OR 1.24; 95% CI 0.70‐2.22). Importantly, however, there was no trend in this cohort’s overall mortality/arrhythmogenesis outcome (HCQ/AZ 17.1%, No‐HCQ/No AZ 17.1%; OR 1.0; 95% CI 0.6‐1.7). CONCLUSIONS: We report from a large retrospective multinational database analysis of COVID‐19 outcomes with HCQ and overall mortality in hospitalized patients. There was no statistically significant increase in mortality and mortality/arrhythmia with HCQ or HCQ/AZ.

The search for safe and effective COVID-19 therapies has accelerated at a frenzied pace. Having advocated for clinicaltrials.gov use in the search for alternative approaches to the COVID-19 patient (1) , searching within the database revealed 3185 COVID-19 clinical trials as of August 31, 2020 . Of these registered COVID-19 clinical trials, 1792 appeared to be treatment trials. Repurposed hydroxychloroquine (HCQ) in prospective randomized clinical trials accounted for 251 of these registered trials with completion dates ranging from February 2020 to December 2029. Presently, HCQ for COVID-19 is being used off-label or within one of these clinical trials.

Although understanding HCQ's efficacy profile in COVID-19 is an immediate concern, its safety profile has dominated recent public conversation. Indeed, the FDA issued additional safety guidance for use of HCQ after the original, now withdrawn,-emergency use authorization (EUA) (2) , which was largely stimulated by Adverse Event Reporting System (AERS) case reports (3) and a retrospective analysis evaluating outcomes of HCQ use in hospitalized United States veterans with COVID-19-. (4) Within this investigation, reported mortality rates were doubled in patients taking HCQ compared with those not receiving HCQ; findings that had an immediate impact on care of patients with COVID-19. Importantly, HCQ's most concerning adverse feature, especially in patients at risk, is its likelihood to prolong the QT-interval, increasing the risk for polymorphic ventricular tachycardia.

The current evidence base for HCQ's safety in COVID-19 largely consists of inferential studies (5), case reports (3), public anecdotes (6), uncontrolled, severely limited and conflicting studies (4, 7, 8) , and a singular randomized, but open label investigation (9) with pitfalls (10) . Through an evaluation of a multinational electronic database of administrative and medical records containing "real world" COVID-19 patients and their respective treatments, we sought to provide further clarity on the safety of HCQ in the treatment of COVID-19.

This article is protected by copyright. All rights reserved

The study used a new-user design in which the drug exposure started within 48 hours after the hospitalization with a confirmed diagnosis of COVID-19. The design allowed the elimination of patients beginning HCQ when decompensation occurred, a prominent concern observed in earlier analyses (11) . Additional sensitivity analyses using a negative control outcome (bleeding time) with no known causal relationship with the target medications were used to assess the influence of unmeasured confounding variables (12). No active comparator treatments were included since to date there are no treatments with known efficacy for COVID-19. Propensity matching was used to control for any measured confounding variables previous to the drug exposure. The cohorts exposed to the target treatments (HCQ alone and HCQ plus azithromycin [AZ]) were compared in pairs with cohorts exposed to no HCQ and no HCQ plus AZ treatments.

TriNetX, Inc., Cambridge, MAis a global federated health research network combining real-time access to longitudinal electronic medical records and administrative claims. Participating health care organizations span a wide range of geographies, age groups, and income levels. Details of and use of the network by our team have been described elsewhere. (13, 14) The TriNetX platform is Health Insurance Portability and Accountability Act ( HIPAA) and General Data Protection Regulation (GDPR) compliant.

All consecutive patients from the known TriNetX universe were included if they had a COVID-19 diagnosis (based on ICD-10 codes) and results for any of the laboratory tests used to identify the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (see used codes in Supplementary   Table) . Included patients were taken between January 20, 2020 and May 14, 2020. We excluded patients who were not hospitalized, and individuals younger than 18 or older than 90 years of age.

Also excluded were patients receiving HCQ greater than 48 hours after admission.

This article is protected by copyright. All rights reserved

The target treatments considered were HCQ and HCQ plus AZ. The exposure started within 48 hours after hospitalization.

The primary outcome was all-cause mortality within 30 days follow-up. An additional outcome combining mortality and an arrhythmogenic diagnosis (see Supplement Table for used coding) was considered based on the well-known arrhythmogenic effects of both HCQ and AZ.

The index dates were between January 20, 2020 and May14, 2020 when the patients met the inclusion/exclusion criteria. Follow-up started one day after the index date and ended when either the outcomes of interest (death or arrhythmogenic diagnoses) or 30 days after the index date (whichever came first) occurred.

A sample size was calculated based on 25% mortality in patients with HCQ and 10% mortality for patients with no HCQ as reported in the Veterans Administration (VA) study (4) . Based on a twosided test with 80% power, an alpha level of 0.05 and the above mentioned mortality rates, it was determined that a minimum of 220 patients (110 in each arm) would be required to detect a difference between the two groups.

Descriptive statistics were presented as frequencies with percentages for categorical variables as a mean +/-standard deviation (SD) for continuous measures. Baseline characteristics were compared using a Pearson chi-squared test for categorical variables and an independent samples t-test for continuous variables. To account for differences in baseline characteristics between the groups, a propensity score matching (PSM) model was developed using logistic regression to derive well matched groups for comparative outcomes analysis.

This article is protected by copyright. All rights reserved Briefly, the TriNetX platform uses a logistic regression to obtain the listed propensity scores within each covariate selected with the use of the Python libraries (NumPy and sklearn). The platform also runs the PSM in R code to compare and to verify the outputs. The final step in verification uses a nearest-neighbor matching algorithm with the tolerance level of 0.01 and a difference between propensity scores no greater than 0.1. Mortality was displayed in the PSM cohorts using the Kaplan Meier method, and the statistical significance of the differences between groups was assessed with the Log-Rank Test. To protect patient health information, patient counts were rounded up to the nearest 10. We made every effort to mitigate these results by using a large sample size.

We received an exemption from the Charleston Area Medical Center IRB since only aggregated counts, statistical summaries of de-identified information, and no protected health information were received.

A total of 25,958 patients taken between January 20, 2020 and May 14, 2020 with a diagnosis of COVID-19 were identified using the TriNetX COVID-19 Research Network. The majority of patients were US-based with a distribution as follows: northeast (25%), Midwest (16%), south (14%), and west (11%); 34% of the cohort was from outside the US. Of those hospitalized (n=3012), 367 (12.2%) were on HCQ (HCQ group) and 2645 (87.8%) were not on HCQ (No-HCQ group). Of those hospitalized in the combined analysis (n=2308), 8.8% were on HCQ+AZ and 91.2% were on neither medication. Patients in the HCQ or in the HCQ plus AZ groups had a higher prevalence of key comorbidities including hypertension, diabetes, obesity, coronary artery disease, chronic obstructive pulmonary disease, nicotine dependence, and history of stroke and were treated more often with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (Tables 1 and 2) .

Comparisons between the cohorts treated with and without HCQ Before PSM, death occurred in 13.1% in the HCQ group and in 12.8% in the No-HCQ group (Table   3 ). PSM yielded two well matched cohorts of 367 patients each who were or were not treated with Accepted Article HCQ (Table 1 ). In these PSM cohorts, all-cause mortality occurred in 13.1% in the HCQ group and in 13.6% in the No-HCQ group (Table 3 ). In these propensity matched cohorts, the composite outcome of mortality and arrhythmogenic diagnoses occurred in 17.4% in the HCQ group and in 17.7% in the No-HCQ group Kaplan Meier survival analysis confirmed the lack of statistically significant association between HCQ and all-cause mortality as well as the combined all-cause mortality plus arrhythmogenic diagnoses outcome ( Figure 1 ).

In the non-matched cohorts, there was an all-cause mortality of 14.4% in the HCQ plus AZ group and 13.3% in the No-HCQ/ No-AZ group (Table 3) . Based on PSM, two well matched cohorts of 199 patients each who were or were not treated with HCQ and AZ were identified ( Table 2 ). In the PSM cohorts treated with and without HCQ plus AZ, there was no significant difference in all-cause mortality between groups (14.6% in the HCQ plus AZ group and 12.1% in the No-HCQ/No-AZ group). In the propensity matched cohorts treated with and without HCQ plus AZ, there were identical percentages (17.1% in both groups) of mortality and arrhythmogenic diagnoses (Table 3) .

Kaplan Meier survival analysis indicated no statistically significant association between HCQ plus AZ use and all-cause mortality in either the unmatched or PSM matched cohorts. (Figure 2 ).

Similarly, there was no statistically significant association between HCQ plus AZ and the combined all-cause mortality plus arrhythmogenic diagnoses in the PSM matched cohorts ( Figure 2 ).

between the cohorts treated with and without HCQ suggesting the absence of a significant unmeasured confounding that would explain the results of the primary outcome (all-cause mortality;

. Additionally, two independent analyses were conducted in order to validate the primary analysis. We explored these endpoints using the diamond and research networks within the TriNetX platform. The diamond network is made of health care organizations (HCOs) which include

This article is protected by copyright. All rights reserved ambulatory care and medical and pharmacy claims data from 92 HCOs. The research network is made of 40 HCOs. These differing research networks are defined by varying agreements between HCOs and TriNetX. Ensuing results from the diamond and research network data can be found in the Supporting Information section. Substantively, results of these analyses were consistent with primary findings.

Based on promising cell culture data from chloroquine's impact on SARS-CoV (15), HCQ, largely due to its known less toxic profile, was considered to be an ideal COVID-19 treatment candidate.

Briefly, HCQ may reduce both the viral entry of COVID-19 into hosts and decrease the inflammatory response. This alkaline drug can inhibit the pH-dependent portions of viral replication (16) . Entry by endocytosis is disrupted by HCQ due to the need for a low pH in order to release viral nucleic acids (16) . HCQ also decreases production of tumor necrosis factor (TNF) α and interleukin 6, which have been found to be upregulated in COVID-19 infection and can create an overabundance of inflammation (17) . HCQ also decreases the expression of TNFα receptors, reducing signaling (16) .

Uncertainty does exist, though, whereas HCQ may actually increase viral load initially through its anti-inflammatory properties (18) .

Converse to its antiviral properties, HCQ possesses actions which may be detrimental, especially in the patient with significant cardiovascular (CV) morbidity. Most notable is its potential to provoke polymorphic ventricular tachycardia (including torsades de pointes -TdP) via prolongation of the QT interval through various mechanisms including a block of the voltage-gated ion channel that controls the rapid component of the delayed rectifier potassium current (IKr). (19) Moreover, AZ, possessing a similar independent QT prolonging effect, likely increases this risk when used concomitantly with HCQ. Fortunately, TdP is often self-terminating; but if sustained, it can degenerate into ventricular fibrillation in approximately 10% of cases and cause sudden cardiac death (20) . Importantly, in a document specifically examining the cardiotoxicity of antimalarial agents, the WHO Evidence Review Group states that QT prolonging antimalarials, including HCQ, have been associated with a

This article is protected by copyright. All rights reserved very low risk of cardiotoxicity (21) . Although somewhat limited by lack of a priori systematic investigation into cardiac effects, this examination was comprehensive, including various analyses of published studies, reviews, pharmacovigilance registries, and manufacturer data repositories. 

This article is protected by copyright. All rights reserved shown reduced severity and course of disease with HCQ, compared with placebo, without detecting serious adverse effects, although others have suggested no difference in outcome from conventional treatment (24) .

In March 2020, the earlier cited French data were published by Gautret and colleagues (7). This was an open-label non-randomized trial of 36 patients diagnosed with COVID-19 (20 HCQ; 16 control).

Six of the 20 patients in the HCQ group were also prescribed AZ. The main outcome was viral carriage at Day 6. Impressively, patients in the HCQ treatment group were significantly more likely to test negative than patients in the ill-defined control group (70% vs 12.5%, p<0.001, respectively).

All 6 patients treated with the combination of HCQ and AZ tested negative on Day 6. Substantive limitations exist within this trial, including the open label, non-randomized design, number of patients lost to follow-up, control cohort recruited from a different medical center, viral load conversion after testing negative, and lack of intent-to-treat analysis.

The aforementioned trials were devoid of a mortality endpoint and were not designed as such, instead having surrogate and symptomatology outcomes. Furthermore, the relationship of viral load and morbidity/mortality is largely unknown. However, independent of this fact, if a relationship of viral load and transmission exists, this might be a worthy societal therapeutic pursuit.

As we patiently awaited findings from prospective double-blinded controlled experiments, additional FDA guidance ensued reminding providers that HCQ should not be used (even within the now withdrawn EUA) outside the hospital setting or within a clinical trial for treatment of COVID-19.

This governmental response was stimulated from AERS reports (3) and a relatively small retrospective VA trial of all male and predominantly black patients hospitalized with COVID-19 that showed an association of higher mortality with HCQ use (4) . In this unpublished and non-peerreviewed trial, treating COVID-19 with HCQ was associated with an increase in mortality. Mortality in this sample of 368 patients was 27.8%, 22.1%, and 11.4% in the HCQ, HCQ/AZ, and no HCQ groups, respectively. These concerning findings accelerated our current investigation. We believed

This article is protected by copyright. All rights reserved our propensity matched cohort study, being more gender-and ethnicity-inclusive, and representing a larger sampling would add to the growing evidence.

Our findings do not substantiate the work of the VA study by Magagnoli 

This fact combined with the study's inconsistent 30-day and long term findings provoked further need for study of HCQ's association with mortality.

This article is protected by copyright. All rights reserved Geleris et al shared results from a single center retrospective cohort of 811 COVID-19 patients receiving HCQ compared to 274 (n=565 unadjusted pre-match) patients not receiving HCQ. (26) As with our findings, there was no significant association between HCQ and the combined endpoint of intubation or death (HR, 1.04, 95% CI, 0.82-1.32). Experience from a single center may limit its generalizability as does its lack of bifurcating its composite outcome. It is uncertain if their mortality outcome in isolation would emulate our findings.

In our analysis, HCQ was devoid of an overall mortality difference (HCQ 13.1%, No HCQ 13.6%).

When combined with AZ, although statistically insignificant, the HCQ cohort had an overall mortality rate of 14.6% compared with the propensity matched No HCQ/No AZ cohort's rate of 12.1%. Importantly, however, there was no trend in this cohort's overall mortality/arrhythmogenesis outcome (HCQ/AZ 17.1%, No HCQ/No AZ 17.1%; OR 1.0 95% CI 0.6-1.7); and the combination group could quite possibly represent a sicker group despite the careful matching (i.e., unmeasured covariates).

in the New York metropolitan region did not find an effect of HCQ (HR 1.08; 95% CI 0.63-1.85) or HCQ/AZ (HR 1.35; 95% CI 0.76-2.40) on mortality relative to no HCQ or AZ. After adjustment, there were no significantly different abnormal ECG findings in the HCQ or HCQ/AZ groups. (27) A series of recent COVID-19 investigations now add weight to the premise of HCQ safety in a hospitalized population. Indeed, three of these investigations (28) (29) (30) produced HRs ranging from 0.487 to 0.684, all statistically significant and demonstrating mortality benefit with HCQ. However, two other studies with arguably superior designs (9, 31) did not reveal a mortality benefit with HCQ with a RR of 1.09 (9) and OR of 1.21 (31) .

The safety profile of HCQ-treated COVID-19 patients in the ambulatory setting has recently been demonstrated by Boulware (32) and Skipper (33) . Unlike the touted RECOVERY trial (9), these randomized investigations were both blinded and placebo-controlled. In patients at high risk for developing COVID-19, there was a non-statistically significant 17% relative risk reduction of developing COVID-19 when taking prophylactic HCQ (n=821) (32) 

This article is protected by copyright. All rights reserved nonsignificant 6% absolute risk reduction in COVID-19 symptomatology in 423 ambulatory nonhospitalized COVID-19 patients (33) .Both investigations lacked sufficient sample size to demonstrate statistically meaningful findings. Most important, and common to these hospital and ambulatorybased trials, is the fact of a favorable cardiotoxicity profile of HCQ in COVID-19 patients.

It appears that the story of HCQ's use in hospitalized COVID-19 patients is coming to an end, largely due to its lack of efficacy in the RECOVERY trial (9) . Despite the trial's shortcomings (10), the findings have had an indelible impact on several other awaited trials, among which, are SOLIDARITY (34) and ORCHID (35) . Upon probing of several investigators of ongoing trials, it is likely that the medical community will not have additional robust data of HCQ use in hospitalized patients with COVID-19. If able to withstand existing pressures to terminate, we can be hopeful that additional data will be forthcoming regarding the utility of HCQ prophylaxis against COVID-19 in ambulatory settings (36).

Inasmuch, present recommendations from the NIH's Treatment Guidelines Panel recommends against the use of HCQ for treatment of COVID-19 in hospitalized patients (37). When adding AZ to HCQ, they recommend against except in a clinical trial. In non-hospitalized patients, the guidelines recommend against the use of HCQ except in a clinical trial.

In early April 2020, the American College of Cardiology, American Heart Association, and Heart Rhythm Society warned providers to use caution when considering HCQ and AZ to treat COVID-19 especially if the patient has CV disease. (38) Our data adds support to this advice. Further, Giudicessi et al (39) provides not only the review of modifiable and nonmodifiable risk factors for drug-induced TdP, but also risk mitigating approaches to HCQ use in COVID-19.

Our results demonstrated that short-term use of HCQ with or without AZ is not associated with a higher overall mortality. QT lengthening is a known effect associated with both HCQ and AZ.

Additive or synergistic effects could lead to TdP. Although there was no benefit of HCQ in hospitalized patients with COVID-19, the current trial builds confidence around the safety profile for

This article is protected by copyright. All rights reserved short term use of HCQ in COVID-19. Furthermore, these results provide support for continued investigation in the ambulatory setting (36, 40).

Limitations of this analysis include: 1) the observational retrospective nature of the study and associated inherent limitations, such as selection bias; 2) residual confounders, although we took into consideration known COVID-19 comorbidities; 3) granular data regarding medication dosages were not available; 4) other QT-prolonging medications not considered; and 5) QT intervals unavailable within the dataset.

We report from a large retrospective multinational database analysis of COVID-19 outcomes with HCQ and overall mortality in hospitalized patients. This propensity matched study showed no association of an increase in overall mortality or other safety signal with HCQ or HCQ/AZ in hospitalized patients with COVID-19. 

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved 

Cardiovascular Disease Novel Coronavirus and the Search for Investigational Therapies

COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and

Pharmacovigilance Memorandum Department of Health and Human Services 2020

Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19

Lancet Rheumatol. 2020. 6. @realDonaldTrump. HYDROXYCHLOROQUINE & AZITHROMYCIN, taken together, have a real chance to be one of the biggest game changers in the history of medicine. the FDA has moved mountains -Thank You! Hopefully they will BOTH (H works better with A

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial

Active-comparator design and new-user design in observational studies

Casual Inference for Statistics, Social, and Biomedical Sciences: An Introduction

Use of electronic health data in clinical development

Sex Differences in COVID-19

Case Fatality Rate: Insights From a Multinational Registry

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Effects of chloroquine on viral infections: an old drug against today's diseases?

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed

Of chloroquine and COVID-19

Predicting drug-induced QT prolongation and torsades de pointes

Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study

The cardiotoxicity of antimalarials World Health Organization Malaria Policy Advisory Committee

Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease

Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit

Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease

Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Association of

Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants

Risk Factors for Mortality in Patients with COVID-19 in New York City

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Solidarity" clinical trial for COVID-19 treatments

Outcomes Related to COVID-19 Treated with Hydroxychloroquine Among In-patients with

HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial